ArticleRSC advances2025
Design and synthesis of coumarin-based pyrazole-pyrazoline hybrid derivatives and their photophysical, antimicrobial, sensing and computational studies.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Three privileged scaffolds, one pipeline: chalcones, pyrazolines and pyrazoles in drug discovery and fluorescent sensing.RSC medicinal chemistry · 2026Review
- Coumarin hybrids as privileged therapeutic scaffolds: biological activities, mechanistic insights, and therapeutic potential.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent times, nitrogen-containing multi-heterocyclic compounds have emerged as valuable scaffolds in the field of medication development because of their broad spectrum of biological activities. In this context, we designed and synthesized new multi-heterocyclic coumarin-based pyrazole-pyrazoline hybrids (4a-4r) through a molecular hybridization approach. The green metrics assessment results revealed that the current molecular hybridization approach is environmentally benign and provides excellent green certification for a safe and sustainable environment. After successful structural characterization, all compounds were evaluated for their antimicrobial potential against various microbial strains. The results of antimicrobial studies showed that compound 4c was most active against
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.